Johnson & JohnsonvsKiniksa Pharmaceuticals International

JNJ and KNSA stock compared: price, dividend, valuation and results, from SEC filings.

KNSA

Kiniksa Pharmaceuticals International, plc

$94.00

Value $7.0B

-1.10%
KNSA's page

Johnson & Johnson (JNJ) has a market value of $639B and Kiniksa Pharmaceuticals International (KNSA) $7.0B. Over the last year, with dividends, JNJ moved +35.5% and KNSA +127.7%. The P/E is 39.7 for JNJ and 63.7 for KNSA. Dividend yield: JNJ 1.99%, KNSA none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    JNJ$639B

    KNSA$7.0B

    JNJ is 92 times KNSA

  • Revenue, 12 months

    JNJ$99.3B

    KNSA$946M

    JNJ is 105 times KNSA

  • Net income, 12 months

    JNJ$16.1B

    KNSA$110M

    JNJ is 147 times KNSA

  • Operating margin

    JNJ–

    KNSA13.8%

  • ROIC

    JNJ12.4%

    KNSA15.9%

    3.5 points apart

  • P/E

    JNJ39.7

    KNSA63.7

    KNSA is 1.6 times JNJ

  • Dividend yield

    JNJ2.0%

    KNSA0.0%

    2.0 points apart

  • 5-year return

    JNJ+87.6%

    KNSA+644.3%

    556.7 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

JNJ+87.6%

KNSA+644.3%

25050075020222023202420252026
Returns by period
PeriodJNJWith dividendsKNSAWith dividends
1 year since November 18, 2025+35.5%Price +32.5%+127.7%Price +127.7%
3 years since November 17, 2023+92.6%+24.4% a yearPrice +76.9%+498.3%+81.5% a yearPrice +498.3%
5 years since November 18, 2021+87.6%+13.4% a yearPrice +63.2%+644.3%+49.4% a yearPrice +644.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

JNJJohnson & JohnsonKNSAKiniksa Pharmaceuticals International

Valuation

JNJKNSA
Valuation
Price$264.96$94.00
Market value$639B$7.0B
Enterprise value (EV)$666B$6.4B
P/E39.763.7
P/E, 5-year median21.955.0
P/B7.89.8
EV/EBIT37.649.1
Free cash flow yield3.2%2.8%

Results and growth

JNJKNSA
Results and growth
Revenue, 12 months$99.3B$946M
Net income, 12 months$16.1B$110M
Free cash flow, 12 months$20.6B$197M
Earnings per share, 12 months$6.59$1.31
Revenue growth, year on year6.1%60.1%
Revenue growth a year, past+2.7%over 5 years+104.8%over 4 years
EPS growth a year, past+14.9%over 5 years–

Margins and returns on capital

JNJKNSA
Margins and returns on capital
Gross margin67.6%90.2%
Operating margin–13.8%
Net margin16.2%11.6%
ROIC12.4%15.9%
ROE19.7%17.8%

Balance sheet

JNJKNSA
Balance sheet
Cash$17.2B$569M
Total debt$44.7B$7.9M
Net debt / EBITDA1.1-4.3
Interest cover18.0×–

Dividends and buybacks

JNJKNSA
Dividends and buybacks
Dividend yield2.0%–
Dividend per share, 12 months$5.28–
Dividend growth a year, past+5.3%over 5 years–
Buyback yield0.9%–
Shareholder yield2.9%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: JNJ or KNSA

Didn't find what you were looking for?

Ask us
Which is bigger, Johnson & Johnson or Kiniksa Pharmaceuticals International?

By market value, Johnson & Johnson ($639B) is about 91.5 times Kiniksa Pharmaceuticals International ($7.0B), at today's prices.

How did JNJ and KNSA stock do over the last 5 years?

Since November 18, 2021, JNJ's price moved +63.2% and KNSA's +644.3%. With dividends: JNJ +87.6% (+13.4% a year), KNSA +644.3% (+49.4% a year). Past returns do not predict future ones.

Which pays the higher dividend, JNJ or KNSA?

The dividend yield at today's price is 1.99% for Johnson & Johnson and none for Kiniksa Pharmaceuticals International. Over the last twelve months they paid $5.28 and – per share.

What is the P/E of JNJ and KNSA?

At today's price, the P/E is 39.7 for JNJ and 63.7 for KNSA. The median of the last five years was 21.9 and 55.0, which shows where each stands against its own past.

Which has the higher profit margins, Johnson & Johnson or Kiniksa Pharmaceuticals International?

Over the last twelve months, the net margin was 16.2% for Johnson & Johnson and 11.6% for Kiniksa Pharmaceuticals International, and the operating margin – and 13.8%. Revenue was $99.3B and $946M.

Which is the better investment, Johnson & Johnson or Kiniksa Pharmaceuticals International?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.